IS8142A - Læknislyf gagnleg til meðferðar á verkjum - Google Patents

Læknislyf gagnleg til meðferðar á verkjum

Info

Publication number
IS8142A
IS8142A IS8142A IS8142A IS8142A IS 8142 A IS8142 A IS 8142A IS 8142 A IS8142 A IS 8142A IS 8142 A IS8142 A IS 8142A IS 8142 A IS8142 A IS 8142A
Authority
IS
Iceland
Prior art keywords
pain
treatment
medication useful
medication
useful
Prior art date
Application number
IS8142A
Other languages
English (en)
Inventor
J. Kyle Donald
Sun Qun
Tafesse Laykea
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of IS8142A publication Critical patent/IS8142A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS8142A 2003-06-12 2005-11-23 Læknislyf gagnleg til meðferðar á verkjum IS8142A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47774403P 2003-06-12 2003-06-12
PCT/US2004/019189 WO2005004866A1 (en) 2003-06-12 2004-06-14 Therapeutic agents useful for treating pain

Publications (1)

Publication Number Publication Date
IS8142A true IS8142A (is) 2005-11-23

Family

ID=34061917

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8142A IS8142A (is) 2003-06-12 2005-11-23 Læknislyf gagnleg til meðferðar á verkjum

Country Status (28)

Country Link
US (3) US7683063B2 (is)
EP (3) EP2060260A1 (is)
JP (2) JP5269315B2 (is)
KR (2) KR100896497B1 (is)
CN (2) CN101863877A (is)
AR (1) AR044688A1 (is)
AT (2) ATE369133T1 (is)
AU (1) AU2004255169B2 (is)
BR (1) BRPI0411241A (is)
CA (1) CA2528920C (is)
CY (1) CY1108738T1 (is)
DE (2) DE602004008069D1 (is)
DK (1) DK1862458T3 (is)
EA (1) EA009593B1 (is)
ES (1) ES2317623T3 (is)
GE (1) GEP20084488B (is)
IL (1) IL172418A (is)
IS (1) IS8142A (is)
MA (1) MA27908A1 (is)
MX (1) MXPA05013587A (is)
MY (1) MY142655A (is)
NO (1) NO20060192L (is)
PL (1) PL1862458T3 (is)
PT (1) PT1862458E (is)
SI (1) SI1862458T1 (is)
TW (1) TWI287010B (is)
WO (1) WO2005004866A1 (is)
ZA (1) ZA200508744B (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
NZ545506A (en) * 2003-07-24 2009-11-27 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1867644T1 (sl) 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
TW200738232A (en) * 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR100801278B1 (ko) * 2006-08-29 2008-02-04 삼성전기주식회사 하이브리드형 광도파로 센서
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
EP2091936B1 (en) * 2007-04-27 2013-05-15 Purdue Pharma LP Therapeutic agents useful for treating pain
JP4657384B2 (ja) 2007-05-03 2011-03-23 ファイザー・リミテッド ナトリウムチャンネルモジュレーターとしての2−ピリジンカルボキサミド誘導体
CA2708320A1 (en) * 2007-08-09 2009-02-19 Abbott Laboratories Amide derivatives as trpv1 antagonists
US8084616B2 (en) 2007-10-24 2011-12-27 Abbott Laboratories TRPV1 antagonists
CN102131503A (zh) 2008-06-30 2011-07-20 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
CA2837178C (en) 2011-06-22 2016-09-20 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013146970A1 (ja) * 2012-03-29 2013-10-03 第一三共株式会社 新規キノリン誘導体
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
KR102459256B1 (ko) * 2016-06-23 2022-10-25 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
JP2019522032A (ja) 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ.ベー. 前立腺癌の治療方法
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP6964506B2 (ja) * 2017-12-19 2021-11-10 ライオン株式会社 錠剤及び錠剤の製造方法
IL275658B2 (en) 2017-12-27 2024-04-01 St Jude Childrens Res Hospital Inc Small molecule modulators of pantothenate kinases
AU2018397486A1 (en) 2017-12-27 2020-08-13 Coa Therapeutics, Inc. Methods of treating disorders associated with castor
RU2744162C1 (ru) * 2020-03-18 2021-03-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ПГФА Минздрава России) Анальгетическое средство на основе 5-(2-аминопропил)-6-оксо-3,4-дифенилпирроло[3,4-c]пиразола
CN115536648B (zh) * 2021-06-29 2024-09-17 深圳开悦生命科技有限公司 一类抑制rna解旋酶dhx33的多环化合物及其应用
CN113061593B (zh) * 2021-04-02 2023-11-10 洛阳华荣生物技术有限公司 一种l-苹果酸脱氢酶突变体及其应用
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114957214A (zh) * 2022-06-22 2022-08-30 九江善水科技股份有限公司 一种氯虫苯甲酰胺中间体的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1363215A (en) * 1973-01-04 1974-08-14 Mullard Ltd Mechanical-electrical transducer
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5053595A (en) * 1982-12-01 1991-10-01 Metcal, Inc. Heat shrink sleeve with high mu material
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
FR2676734B1 (fr) * 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6063930A (en) * 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
CA2274593A1 (en) * 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
US6703362B1 (en) * 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
DE69819345T2 (de) * 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
US6098369A (en) * 1998-07-17 2000-08-08 Bodolay; William A. Apparatus for attaching a reclosable fastener to a flexible material
US6689780B1 (en) * 1998-12-23 2004-02-10 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor Xa
US6635657B1 (en) * 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
WO2000039117A1 (en) * 1998-12-23 2000-07-06 Eli Lilly And Company HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa
GB9907097D0 (en) * 1999-03-26 1999-05-19 Novartis Ag Organic compounds
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ES2311012T3 (es) 2000-03-27 2009-02-01 ABBOTT GMBH & CO. KG Ligandos del receptor d3 de la dopamina para el tratamiento de la adiccion.
ATE479429T1 (de) * 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
JP2003142681A (ja) 2001-10-31 2003-05-16 Sony Corp 絶縁ゲート型電界効果トランジスタを有する半導体装置
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
WO2003066595A2 (en) 2002-02-01 2003-08-14 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
EP2033953A1 (en) 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
US7067509B2 (en) * 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US7129235B2 (en) * 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
NZ545506A (en) * 2003-07-24 2009-11-27 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1867644T1 (sl) 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
EP2091936B1 (en) * 2007-04-27 2013-05-15 Purdue Pharma LP Therapeutic agents useful for treating pain

Also Published As

Publication number Publication date
IL172418A0 (en) 2006-04-10
JP5269315B2 (ja) 2013-08-21
EP1631285A4 (en) 2006-11-02
EP1862458A3 (en) 2008-01-23
DE602004017658D1 (de) 2008-12-18
IL172418A (en) 2011-03-31
SI1862458T1 (sl) 2009-04-30
CA2528920A1 (en) 2005-01-20
ES2317623T3 (es) 2009-04-16
EP2060260A1 (en) 2009-05-20
DE602004008069D1 (de) 2007-09-20
MY142655A (en) 2010-12-15
PT1862458E (pt) 2009-01-20
CN101863877A (zh) 2010-10-20
KR20060012026A (ko) 2006-02-06
KR20090008439A (ko) 2009-01-21
AU2004255169A1 (en) 2005-01-20
CA2528920C (en) 2011-05-03
AR044688A1 (es) 2005-09-21
GEP20084488B (en) 2008-09-25
US20130012541A1 (en) 2013-01-10
WO2005004866A1 (en) 2005-01-20
EP1862458A2 (en) 2007-12-05
NO20060192L (no) 2006-02-07
MA27908A1 (fr) 2006-05-02
US8680118B2 (en) 2014-03-25
EA009593B1 (ru) 2008-02-28
JP2012021000A (ja) 2012-02-02
US7683063B2 (en) 2010-03-23
EA200501820A1 (ru) 2006-06-30
BRPI0411241A (pt) 2006-07-25
MXPA05013587A (es) 2006-03-17
ATE413385T1 (de) 2008-11-15
JP2007504284A (ja) 2007-03-01
TW200508216A (en) 2005-03-01
DK1862458T3 (da) 2009-02-16
CY1108738T1 (el) 2014-07-02
CN1835751B (zh) 2010-06-23
EP1862458B1 (en) 2008-11-05
US20070027159A1 (en) 2007-02-01
ATE369133T1 (de) 2007-08-15
EP1631285A1 (en) 2006-03-08
AU2004255169B2 (en) 2010-08-26
PL1862458T3 (pl) 2009-04-30
CN1835751A (zh) 2006-09-20
KR100896497B1 (ko) 2009-05-08
US20110152324A1 (en) 2011-06-23
TWI287010B (en) 2007-09-21
US8227467B2 (en) 2012-07-24
EP1631285B1 (en) 2007-08-08
ZA200508744B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS8511A (is) Píperasín gagnleg til meðferðar á verkjum
DE60328797D1 (de) Blutbehandlungsgerät
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
NO20053041D0 (no) Behandling av diabetes.
DE60308431D1 (de) Geschäumte Säurebehandlungsflüssigkeit
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
IS7825A (is) Meðferðarfræðileg meðhöndlun
DE602004010856D1 (de) Bohrlochbehandlungsflüssigkeiten
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1678085T3 (da) Fluidbehandlingsindretning
DK1597171T3 (da) Terapeutisk mikroskum
ATA13602003A (de) Therapeutisches behandlungsgerät
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
IS8477A (is) Beta-laktöm til að meðhöndla MTK sjúkdóma
NO20033160D0 (no) Anordning for behandling av gravann
DK1646387T3 (da) Anvendelse af indazol-derivater til behandling af neuropatiske smerter
IS8496A (is) Samsetningar til meðhöndlunar á fjölgunarsjúkdómum
FR2838959B1 (fr) Bassin medical
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.